Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 2/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL745664 | 0.86 | — | — | |
| SCHEMBL215741 | 0.82 | TSHR (0.48) | TSHRHIF1AMAPTFAAHTRPV1 | |
| SCHEMBL2853062 | 0.80 | TSHR (0.44) | TSHRHIF1AMAPTFAAHTRPV1 | |
| SCHEMBL214617 | 0.78 | TSHR (0.33) | TSHRHIF1AMAPTLMNA | |
| SCHEMBL216646 | 0.78 | TSHR (0.33) | TSHRHIF1AMAPTLMNA | |
| SCHEMBL214596 | 0.78 | TSHR (0.33) | TSHRHIF1AMAPTLMNA | |
| SCHEMBL10763677 | 0.78 | LMNA (0.46) | TSHRHIF1AMAPTFAAHTRPV1 | |
| SCHEMBL215495 | 0.77 | TSHR (0.34) | TSHRHIF1AMAPT | |
| SCHEMBL14997310 | 0.77 | — | — | |
| Glutaral SCHEMBL7174412 | 0.77 | LMNA (0.57) | TSHRHIF1AMAPTFAAHTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2430024-A1 | [1,2,4]TRIAZOLO [4,3-B]PYRIDAZINES AS LIGANDS OF THE ANDROGEN RECEPTOR | AstraZeneca AB (SE) | 2012-03-21 | — | — | EP | disclosed |
| WO-2010131022-A1 | [1,2,4] TRIAZOLO [4,3-B] PYRIDAZINES AS LIGANDS OF THE ANDROGEN RECEPTOR | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | WO | disclosed |
| US-20100292222-A1 | CHEMICAL COMPOUNDS 751 | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292222-A1 | CHEMICAL COMPOUNDS 751 | AR, NR5A1, KLK3 | TSHR 907/4885HIF1A 565/4885MAPT 2874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.